AstraZeneca Pharma India is planning to exit the manufacturing site in Bangalore, in due course, as a part of its ongoing strategic review of its Global Manufacturing and Supply Network. The Company will position the manufacturing site for sale in a fully operational manner and begin a search for a buyer who can also act as a Contract Manufacturing Organisation (CMO) for Company’s products currently manufactured or packaged at this site, subject to receipt of necessary statutory approvals.
The Company is fully cognizant of the impact this change can bring and its first responsibility will be towards its employees and meeting the needs of its patients by ensuring an uninterrupted supply of medicines.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |